These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 36799423)
1. Cyclopeptide-based Anti-liver Cancer Agents: A Mini-review. Li T; Li T; Wang Z; Jin Y Protein Pept Lett; 2023; 30(3):201-213. PubMed ID: 36799423 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of cyclopeptide GG-8-6 and its analogues as anti-hepatocellular carcinoma agents. Chen JT; Ma R; Sun SC; Zhu XF; Xu XL; Mu Q Bioorg Med Chem; 2018 Feb; 26(3):609-622. PubMed ID: 29310863 [TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of Longicalcynin A analogues, as anticancer cyclopeptides. Gholibeikian M; Bamoniri A; HoushdarTehrani MH; Fatemeh Mirjalili BB; Bijanzadeh HR Chem Biol Interact; 2020 Jan; 315():108902. PubMed ID: 31747558 [TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis. Miura JT; Gamblin TC Surg Oncol Clin N Am; 2015 Jan; 24(1):149-66. PubMed ID: 25444473 [TBL] [Abstract][Full Text] [Related]
5. Natural Cyclopeptides as Anticancer Agents in the Last 20 Years. Zhang JN; Xia YX; Zhang HJ Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921480 [TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Tsochatzis EA; Germani G; Burroughs AK Semin Oncol; 2010 Apr; 37(2):89-93. PubMed ID: 20494700 [TBL] [Abstract][Full Text] [Related]
7. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Tung-Ping Poon R; Fan ST; Wong J Ann Surg; 2000 Jul; 232(1):10-24. PubMed ID: 10862190 [TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146 [TBL] [Abstract][Full Text] [Related]
9. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Au JS; Frenette CT Gut Liver; 2015 Jul; 9(4):437-48. PubMed ID: 26087860 [TBL] [Abstract][Full Text] [Related]
10. Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis. Jin PP; Shao SY; Wu WT; Zhao XY; Huang BF; Fu QH; Que RS; Hu QD Jpn J Clin Oncol; 2018 Dec; 48(12):1058-1069. PubMed ID: 30272196 [TBL] [Abstract][Full Text] [Related]
11. Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Kim JH; Won HJ; Shin YM; Kim SH; Yoon HK; Sung KB; Kim PN Ann Surg Oncol; 2011 Jun; 18(6):1624-9. PubMed ID: 21445671 [TBL] [Abstract][Full Text] [Related]
12. Advances in managing hepatocellular carcinoma. Reataza M; Imagawa DK Front Med; 2014 Jun; 8(2):175-89. PubMed ID: 24810646 [TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. Tsochatzis EA; Fatourou E; O'Beirne J; Meyer T; Burroughs AK World J Gastroenterol; 2014 Mar; 20(12):3069-77. PubMed ID: 24695579 [TBL] [Abstract][Full Text] [Related]
14. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer. Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641 [TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience. Idilman I; Peynircioğlu B; Cil BE; Doğanay Erdoğan B; Yalçın S; Bayraktar Y; Kav T; Altundağ K; Balkancı F Turk J Gastroenterol; 2013; 24(2):141-7. PubMed ID: 23934461 [TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1. Giunchedi P; Maestri M; Gavini E; Dionigi P; Rassu G Expert Opin Drug Deliv; 2013 May; 10(5):679-90. PubMed ID: 23406440 [TBL] [Abstract][Full Text] [Related]
17. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Shin SW Korean J Radiol; 2009; 10(5):425-34. PubMed ID: 19721826 [TBL] [Abstract][Full Text] [Related]
18. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA Trials; 2012 Aug; 13():144. PubMed ID: 22913492 [TBL] [Abstract][Full Text] [Related]
19. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma. Nouri YM; Kim JH; Yoon HK; Ko HK; Shin JH; Gwon DI Korean J Radiol; 2019 Jan; 20(1):34-49. PubMed ID: 30627020 [TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. Rostambeigi N; Dekarske AS; Austin EE; Golzarian J; Cressman EN J Vasc Interv Radiol; 2014 Jul; 25(7):1075-84. PubMed ID: 24861664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]